Core Points - The company has announced its 2024 annual profit distribution plan, which was approved at the shareholders' meeting on May 12, 2025 [1] - The distribution plan involves a cash dividend of RMB 0.818 per 10 shares, totaling RMB 16,801,981.76, based on a total share capital of 205,403,200 shares as of December 31, 2024 [1][4] - The cash dividend will be distributed without issuing new shares or capital reserve transfers, and any unallocated profits will be carried forward to future distributions [1][4] Distribution Plan - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of July 4, 2025 [5] - The ex-dividend date is set for July 7, 2025, and the cash dividends will be directly credited to shareholders' accounts through their custodial securities companies [5][6] Taxation Details - The cash dividend is subject to different tax rates based on the type of shareholder, with specific rates for foreign institutions and individual investors holding pre-IPO restricted shares [4][6] - The company will not withhold individual income tax at the time of distribution; instead, it will be calculated based on the holding period when shares are sold [4] Adjustments - Following the distribution, the minimum selling price for shareholders who committed to not selling their shares within two years post-lockup will be adjusted to RMB 12.19 per share [6] - The company will also adjust the grant and exercise prices for restricted stock options in accordance with its incentive plan after the distribution is completed [6]
湖南达嘉维康医药产业股份有限公司2024年年度权益分派实施公告